APPILI THERAPEUTICS INC-CL A (APLI.CA) Stock Price, Quote, News and Overview
TSX:APLI - Toronto Stock Exchange - CA03783R1073 - Common Stock - Currency: CAD
APLI.CA Quote, Performance and Key Statistics
TSX:APLI (3/7/2025, 7:00:00 PM)
0.035
+0.01 (+16.67%)
The current stock price of APLI.CA is 0.035 CAD.
APLI.CA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.87 | 3.77B | ||
| CRON.CA | CRONOS GROUP INC | N/A | 1.08B | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 928.28M | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 4.93 | 675.16M | ||
| GUD.CA | KNIGHT THERAPEUTICS INC | N/A | 546.47M | ||
| DHT-U.CA | DRI HEALTHCARE TRUST | 3.62 | 495.53M | ||
| ACB.CA | AURORA CANNABIS INC | N/A | 376.34M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 293.01M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 12.54 | 288.91M | ||
| HITI.CA | HIGH TIDE INC | N/A | 278.36M | ||
| TSND.CA | TERRASCEND CORP | N/A | 249.63M | ||
| NGEN.CA | NERVGEN PHARMA CORP | N/A | 198.02M |
Related stock screener links
About APLI.CA
Company Profile
Appili Therapeutics, Inc. is a pharmaceutical company, which acquires and develops novel treatments targeting unmet needs in infectious disease. The company is headquartered in Halifax, Nova Scotia and currently employs 7 full-time employees. The company went IPO on 2019-06-25. The firm is advancing a diverse range of anti-infectives, including ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701 and ATI-1801. LIKMEZ (ATI-1501) is its advanced commercial stage asset, a liquid oral reformulation of the antibiotic metronidazole to treat serious anaerobic and protozoal infections. ATI-1701 is a live-attenuated vaccine for Francisella tularensis (F. tularensis), the bacterium which causes tularemia. ATI-1801 is a topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis.
Company Info
APPILI THERAPEUTICS INC-CL A
#21-1344 Summer Street
Halifax NOVA SCOTIA B3H 0A8 CA
CEO: Armand Balboni
Employees: 9
Company Website: https://appilitherapeutics.com/
Investor Relations: http://appilitherapeutics.com/financial-reports/
Phone: 19024424655
APPILI THERAPEUTICS INC-CL A / APLI.CA FAQ
What is the stock price of APPILI THERAPEUTICS INC-CL A today?
The current stock price of APLI.CA is 0.035 CAD. The price increased by 16.67% in the last trading session.
What is the ticker symbol for APPILI THERAPEUTICS INC-CL A stock?
The exchange symbol of APPILI THERAPEUTICS INC-CL A is APLI and it is listed on the Toronto Stock Exchange exchange.
On which exchange is APLI.CA stock listed?
APLI.CA stock is listed on the Toronto Stock Exchange exchange.
What is APPILI THERAPEUTICS INC-CL A worth?
APPILI THERAPEUTICS INC-CL A (APLI.CA) has a market capitalization of 4.24M CAD. This makes APLI.CA a Nano Cap stock.
How many employees does APPILI THERAPEUTICS INC-CL A have?
APPILI THERAPEUTICS INC-CL A (APLI.CA) currently has 9 employees.
What are the support and resistance levels for APPILI THERAPEUTICS INC-CL A (APLI.CA) stock?
APPILI THERAPEUTICS INC-CL A (APLI.CA) has a support level at 0.03 and a resistance level at 0.04. Check the full technical report for a detailed analysis of APLI.CA support and resistance levels.
Should I buy APPILI THERAPEUTICS INC-CL A (APLI.CA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of APLI.CA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of APLI.CA, evaluating the profitability, health, valuation and growth aspects
- APPILI THERAPEUTICS INC-CL A (APLI.CA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- APPILI THERAPEUTICS INC-CL A (APLI.CA) Sales and EPS estimates to see what analysts future expectations are.
- APPILI THERAPEUTICS INC-CL A (APLI.CA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- APPILI THERAPEUTICS INC-CL A (APLI.CA) Insider and Institutional Ownership to learn about the owners and their transactions.
- APPILI THERAPEUTICS INC-CL A (APLI.CA) Stock Chart to make your own analysis
- APPILI THERAPEUTICS INC-CL A (APLI.CA) Latest news and press-releases to stay up to date.
Does APPILI THERAPEUTICS INC-CL A (APLI.CA) stock pay dividends?
APLI.CA does not pay a dividend.
When does APPILI THERAPEUTICS INC-CL A (APLI.CA) report earnings?
APPILI THERAPEUTICS INC-CL A (APLI.CA) will report earnings on 2025-06-23, after the market close.
What is the Price/Earnings (PE) ratio of APPILI THERAPEUTICS INC-CL A (APLI.CA)?
APPILI THERAPEUTICS INC-CL A (APLI.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.03).
APLI.CA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to APLI.CA. When comparing the yearly performance of all stocks, APLI.CA is a bad performer in the overall market: 61.38% of all stocks are doing better.
APLI.CA Financial Highlights
Over the last trailing twelve months APLI.CA reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS increased by 21.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -188.96% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
APLI.CA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 42% to APLI.CA. The Buy consensus is the average rating of analysts ratings from 9 analysts.